PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Saved in:
| Title: | PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P. |
|---|---|
| Authors: | Janku F; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX., Jegede OA; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA., Puhalla SL; University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA., Konstantinopoulos PA; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA., Meric-Bernstam F; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX., Zwiebel JA; Division of Cancer Treatment and Diagnosis, Investigational Drug Branch, National Cancer Institute, Bethesda, MD., Gray RJ; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA., Wang XV; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA., McShane LM; Division of Cancer Treatment and Diagnosis, Biometric Research Program, National Cancer Institute, Bethesda, MD., Rubinstein LV; Division of Cancer Treatment and Diagnosis, Biometric Research Program, National Cancer Institute, Bethesda, MD., Patton DR; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; City of Hope National Medical Center, Duarte, CA., Takebe N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Ghani S; University of Oklahoma Health Science Center, Oklahoma City, OK., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX., Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA. |
| Source: | JCO precision oncology [JCO Precis Oncol] 2025 Aug; Vol. 9, pp. e2500265. Date of Electronic Publication: 2025 Aug 27. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
